Exelixis Stock Performance
| EXEL Stock | USD 45.40 0.86 1.86% |
On a scale of 0 to 100, Exelixis holds a performance score of 11. The firm shows a Beta (market volatility) of 0.65, which means possible diversification benefits within a given portfolio. As returns on the market increase, Exelixis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Exelixis is expected to be smaller as well. Please check Exelixis' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Exelixis' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Exelixis disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.86) | Five Day Return 11.69 | Year To Date Return 33.77 | Ten Year Return 1.3 K | All Time Return 207.8 |
1 | Disposition of 31167 shares by Smith Julie of Exelixis at 20.5 subject to Rule 16b-3 | 02/27/2025 |
2 | Acquisition by Christopher Senner of 29314 shares of Exelixis at 18.8 subject to Rule 16b-3 | 03/07/2025 |
3 | Orchestra BioMed Holdings, Inc. Reports Q4 Loss, Lags Revenue Estimates | 03/31/2025 |
4 | Acquisition by Smith Julie of 19294 shares of Exelixis at 19.77 subject to Rule 16b-3 | 04/04/2025 |
5 | Citizens JMP reiterates Exelixis stock with 41 target - Investing.com | 04/17/2025 |
6 | Exelixis, Inc. Stock Position Reduced by 13D Management LLC | 05/02/2025 |
7 | Urogen Pharma Reports Q1 Loss, Lags Revenue Estimates | 05/12/2025 |
8 | Invenra Highlights Exelixis Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced ... | 05/13/2025 |
9 | Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat | 05/14/2025 |
10 | Exelixis Target Price Raised by Citigroup Analyst EXEL Stock News | 05/15/2025 |
11 | Price Over Earnings Overview Exelixis | 05/16/2025 |
| Begin Period Cash Flow | 263 M |
Exelixis Relative Risk vs. Return Landscape
If you would invest 3,420 in Exelixis on February 18, 2025 and sell it today you would earn a total of 1,120 from holding Exelixis or generate 32.75% return on investment over 90 days. Exelixis is currently generating 0.4947% in daily expected returns and assumes 3.332% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Exelixis, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Exelixis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exelixis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Exelixis, and traders can use it to determine the average amount a Exelixis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1485
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EXEL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.33 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.49 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Exelixis is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Exelixis by adding it to a well-diversified portfolio.
Exelixis Fundamentals Growth
Exelixis Stock prices reflect investors' perceptions of the future prospects and financial health of Exelixis, and Exelixis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exelixis Stock performance.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 11.54 B | ||||
| Shares Outstanding | 272.71 M | ||||
| Price To Earning | 48.17 X | ||||
| Price To Book | 5.81 X | ||||
| Price To Sales | 5.39 X | ||||
| Revenue | 2.17 B | ||||
| Gross Profit | 2.22 B | ||||
| EBITDA | 710.44 M | ||||
| Net Income | 521.27 M | ||||
| Cash And Equivalents | 1.53 B | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 190.82 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.08 X | ||||
| Book Value Per Share | 7.75 X | ||||
| Cash Flow From Operations | 699.97 M | ||||
| Earnings Per Share | 2.19 X | ||||
| Market Capitalization | 12.38 B | ||||
| Total Asset | 2.95 B | ||||
| Retained Earnings | (98.65 M) | ||||
| Working Capital | 1.06 B | ||||
| Current Asset | 178.66 M | ||||
| Current Liabilities | 52.25 M | ||||
About Exelixis Performance
By examining Exelixis' fundamental ratios, stakeholders can obtain critical insights into Exelixis' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exelixis is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 107.22 | 189.79 | |
| Return On Tangible Assets | 0.18 | 0.09 | |
| Return On Capital Employed | 0.24 | 0.13 | |
| Return On Assets | 0.18 | 0.09 | |
| Return On Equity | 0.23 | 0.10 |
Things to note about Exelixis performance evaluation
Checking the ongoing alerts about Exelixis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exelixis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exelixis had very high historical volatility over the last 90 days | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy |
- Analyzing Exelixis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exelixis' stock is overvalued or undervalued compared to its peers.
- Examining Exelixis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exelixis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exelixis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exelixis' stock. These opinions can provide insight into Exelixis' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.583 | Earnings Share 2.19 | Revenue Per Share | Quarterly Revenue Growth 0.306 | Return On Assets |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.